TILRAY BRANDS NEW O.N. Logo
US88688T2096
A41VMJ

TILRAY BRANDS NEW O.N.

Loading quotes...

Forecast

The analysts' average price target is €58.03 (+2,193.68%). The median is €37.05 (+1,364.43%).

Buy
  4
Hold
  14
Sell
  2

  • Tilray Brands converts $12 million of debt into 2,841,650 common shares

    Tilray Brands carried out private transactions between August 31 and September 8 and issued 2,841,650 unregistered common shares in exchange for $12 million principal amount of its 5.20% convertible senior notes due June 15, 2027. The transactions were with independent third parties and relied on the Section 3(a)(9) exemption of the Securities Act of 1933. » More on de.investing.com


  • Tilray Brands to buy HelloMD and build vertically integrated medical cannabis platform in Canada

    Tilray Brands announced on June 29 that it will acquire HelloMD's Canadian medical cannabis assets after winning a court-approved sale process. The deal pairs HelloMD's digital telehealth and patient engagement platform with Tilray's cultivation, clinical expertise and national fulfillment to create a connected pathway for patients and practitioners. Tilray highlighted opportunities to expand into adjacent wellness categories like sleep and pain support; financial terms were not disclosed. Shares of Tilray are down more than 50% year-to-date. » More on finance.yahoo.com

Financials

In the last quarter, TILRAY BRANDS NEW O.N. had revenue of €221.35m and net profit of -€37.13m
(EUR) August 2026
YoY
Revenue 221.35m 23.51%
Gross profit 66.72m 35.72%
Net profit -37.13m 13,382.06%
EBITDA -11.35m 161.77%

Fundamentals

Metric Value
Market capitalization
€291.5m
Number of shares
111.83m
52-week high/low
€14.01 - €2.60
Dividends No
Beta
1.92
P/E ratio
-2.09
PEG ratio
-0.02
P/B ratio
0.24
P/S ratio
0.34

Company profile

Name
TILRAY BRANDS NEW O.N.
CEO
Irwin David Simon
Headquarters Leamington, on
USA
Website
Sector
Health Care
Industry
Biotechnology
Employees 3,595
🍪

Parqet  uses cookies. Learn more